SVB Wealth’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

SVB Wealth’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-13,500	Closed	-$85K	–	770
2020 Q2	$85K	Buy	+13,500	New	+$51.7K	﹤0.01%	586

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SVB Wealth's SRNE Position: Q3 2020 in Review

SVB Wealth sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2020, closing a stake of 13,500 shares — an estimated $85K sold.

SVB Wealth first reported a position in SRNE in Q2 2020 and held it in 1 quarter. The position peaked at $85K in Q2 2020. 209 funds tracked by Wall St. Rank hold SRNE as of Q3 2020.

SVB Wealth reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
SVB Wealth sold 13,500 Sorrento Therapeutics, Inc. shares in Q3 2020, an estimated $85K.
SVB Wealth first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 1 quarter.
SVB Wealth's Sorrento Therapeutics, Inc. position peaked at $85K in Q2 2020.
209 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2020.

Based on SVB Wealth's 13F filing for Q3 2020, filed 10 Nov 2020.